HOUSTON, Jan. 4 /PRNewswire/ — SeqWright, Inc., an international leader in the field of contract genomics services, announced today its selection by Third Wave Technologies, Inc. to participate in the clinical trial for two human papillomavirus (HPV) screening products. Third Wave Technologies is currently conducting a clinical trial for the evaluation of two new HPV in vitro diagnostic molecular assays: a screening test for the detection of 14 high-risk types of HPV and a genotyping test to specifically detect and identify HPV types 16 and 18. These two HPV types have been identified as the cause of approximately 70% of cervical cancer cases. SeqWright will be performing all of the sequencing and associated analyses in support of this HPV clinical trial.
SeqWright’s participation in this clinical trial will take advantage of the company’s existing strengths in service genomics and will enable development and implementation of custom sequence analysis procedures. SeqWright has advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.
“It is very exciting for us to support Third Wave’s efforts to bring these two new HPV diagnostic products to market,” said Fei Lu M.D., the Chief Executive Officer at SeqWright. “This is a key health problem and we are privileged to make a contribution.”
“Third Wave has completed a rigorous supplier qualification process and is confident that SeqWright can deliver the quality sequence analysis service required to ensure a successful outcome of the clinical trial of our HPV HR 14 assay and our HPV 16 / 18 assay,” said Kevin Conroy, President and CEO of Third Wave Technologies, Inc.
SeqWright Incorporated is a world-class genomic support organization with more than eleven years of experience specializing in DNA discovery products and customized services designed for scientific researchers from the pharmaceutical, agricultural, biotechnology, government and academic communities. SeqWright’s DNA sequencing services range from large-scale genomic to FDA submission quality sequencing with an accuracy of 100 percent. SeqWright handles all bioinformatics and data management aspects for each project. For additional information about SeqWright and its services, please visit http://www.seqwright.com/ .
About Third Wave Technologies
Third Wave Technologies Incorporated develops and markets molecular diagnostic reagents for a variety of DNA and RNA analysis applications to meet the needs of our customers. The company offers a number of products based on its Invader(R) chemistry for clinical testing. Third Wave offers in vitro diagnostic kits, and analyte specific, general purpose, and research use only reagents for nucleic acid analysis. For more information about Third Wave and its products, please visit the company’s website at http://www.twt.com/ .